Compare TG Therapeutics Inc (TGTX) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Digital Corp — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Western Digital Corp trades at $456.8 (market cap $150.95B). The key difference: Western Digital Corp is far larger — about 19.8× TG Therapeutics Inc's market cap, and Western Digital Corp pays a 0.14% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WDC | |
|---|---|---|
Market Cap | $7.64B | $150.95B |
Sector | Health | Technology |
52-Week High | $59.06 | $746.23 |
52-Week Low | $26.94 | $74.66 |
Enterprise Value | $7.84B | $150.42B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Western Digital (WDC) trades at $454.50, up 3.74% in the last session, with a bearish technical signal but strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $3.56 versus $3.31 expected, highlight robust AI-driven storage demand. The stock is near resistance at $458, with a consensus analyst price target of $665.15 suggesting significant upside potential.
Outlook is positive due to sustained AI infrastructure growth and margin expansion, but risks include valuation concerns and competitive threats. Analyst consensus is strongly bullish with 72% buy ratings, though technical indicators signal near-term caution. Investors should weigh strong earnings momentum against potential volatility from stretched valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
